Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

被引：0
|
作者：
Reider, S. [1 ,2 ]
Watschinger, C. [3 ]
Koch, R. [4 ]
Tilg, H. [4 ]
Moschen, A. [1 ,2 ]
机构：
[1] Johannes Kepler Univ Linz, Linz, Austria
[2] Kepler Univ Hosp, Dept Internal Med 2, Linz, Austria
[3] Johannes Kepler Univ Linz, Dept Internal Med, Christian Doppler Lab Mucosal Immunol, Linz, Austria
[4] Med Univ Innsbruck, Dept Internal Med 1, Innsbruck, Austria
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P206
引用
收藏
页码：I522 / I522
页数：1
相关论文
共 50 条
  • [1] Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
    Shmidt, Eugenia
    Kochhar, Gursimran
    Hartke, Justin
    Chilukuri, Prianka
    Meserve, Joseph
    Chaudrey, Khadija
    Koliani-Pace, Jenna L.
    Hirten, Robert
    Faleck, David
    Barocas, Morris
    Luo, Michelle
    Lasch, Karen
    Boland, Brigid S.
    Singh, Siddharth
    Vande Casteele, Niels
    Sagi, Sashidhar Varma
    Fischer, Monika
    Chang, Shannon
    Bohm, Matthew
    Lukin, Dana
    Sultan, Keith
    Swaminath, Arun
    Hudesman, David
    Gupta, Nitin
    Kane, Sunanda
    Loftus, Edward V., Jr.
    Sandborn, William J.
    Siegel, Corey A.
    Sands, Bruce E.
    Colombel, Jean-Frederic
    Shen, Bo
    Dulai, Parambir S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2461 - 2467
  • [2] Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease"
    Pauwels, Renske W. M.
    de Vries, Annemarie C.
    van der Woude, C. Janneke
    [J]. INFLAMMATORY BOWEL DISEASES, 2019, 25 (05) : E59 - E59
  • [3] Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
    Barre, A.
    Colombel, J. -F.
    Ungaro, R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 896 - 905
  • [4] Predicting Response to Vedolizumab in Inflammatory Bowel Disease
    Meserve, Joseph
    Dulai, Parambir
    [J]. FRONTIERS IN MEDICINE, 2020, 7
  • [5] PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Al Bawardy, Badr
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S703 - S703
  • [6] Effect of obesity on vedolizumab response in inflammatory bowel disease
    Levine, Louis
    Gaidos, Jill K. J.
    Proctor, Deborah D.
    Viana, Artur V.
    Al-Bawardy, Badr
    [J]. ANNALS OF GASTROENTEROLOGY, 2022, 35 (03): : 275 - 280
  • [7] EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Viana, Artur V.
    Al Bawardy, Badr
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S703 - S704
  • [8] Predictors of Vedolizumab Dose Escalation or Cessation in Inflammatory Bowel Disease Patients
    Razvi, Mohammed A.
    Chowdhury, Reezwana
    Parian, Alyssa
    Melia, Joanna
    Truta, Brindusa
    Brant, Steve
    Dudley-Brown, Sharon
    Lazarev, Mark
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S417 - S418
  • [9] PREDICTORS OF ACUTE AND DELAYED VEDOLIZUMAB INFUSION REACTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Gold, Stephanie
    Cohen-Mekelburg, Shirley A.
    Schneider, Yecheskel
    Bosworth, Brian P.
    Steinlauf, Adam F.
    Scherl, Ellen
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S368 - S368
  • [10] Vedolizumab (Entyvio) for Inflammatory Bowel Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1451): : 86 - 88
12345